In the preclinical setting, this also requires the perturbation of ACTG1 in models in which one can evaluate uterine cancer cell interaction with immune cells, such as immune-competent tumor-forming mouse models or co-culture models in vitro. Here, ACTG1 is linked to neoplasm.